Calliditas’ rare disease drug draws $1B+ buyout offer from Japanese buyer
A Japanese conglomerate is offering to buy Calliditas Therapeutics for more than $1 billion in a bid to enter a burgeoning autoimmune disease space. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
